American Society of Clinical Oncology

SHERPA: White

People

  1. Scher
    Scher
  2. Morris
    Morris
  3. Rathkopf
    Rathkopf
  4. Danila
    Danila
  5. Autio
    Autio
  6. Carver
    Carver
  7. Chen
    Chen
  8. Martinez
    Martinez
  9. Slovin
    Slovin
  10. Fox
    Fox

Groups

  1. Department of Medicine (25)
  2. Genitourinary Oncology Service (25)
  3. Solid Tumor Oncology Division (25)
  4. GSK Faculty (6)
  5. Hematologic Malignancies, Division of (5)
  6. Radiology, Department of (5)
  7. Molecular Pharmacology and Chemistry Program Faculty (4)
  8. Sloan Kettering Institute Faculty (4)
  9. Surgery (4)
  10. Urology (4)
Search Within
  1. "2014"
  2. "Howard Scher"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (2)
Groups
  1. Department of Medicine (25)
  2. Genitourinary Oncology Service (25)
  3. Solid Tumor Oncology Division (25)
  4. GSK Faculty (6)
  5. Hematologic Malignancies, Division of (5)
  6. Radiology, Department of (5)

More Groups

People
  1. Howard Scher (25)
  2. Michael Morris (9)
  3. Dana Rathkopf (8)
  4. Daniel Danila (5)
  5. Karen Autio (4)
  6. Brett Carver (3)

More People

Years
  1. 2014 (25)
Publications
  1. Journal of Clinical Oncology (24)
  2. American Society of Clinical Oncology Educational Book (1)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure
    Journal Article

    Scher, H. I.
    American Society of Clinical Oncology Educational Book (2014)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Lee, C.; Maclean, D.; Tejura, B.; Webb, I. J.; Borgstein, N.; Dreicer, R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302
    Meeting Abstract

    Ricci, D. S.; Li, W. M.; Griffin, T. W.; Gormley, M.; Henitz, E.; Ryan, C. J.; de Bono, J. S.; Attard, G.; Van Den Eertwegh, A. J. M.; Schrijvers, D. L.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment
    Meeting Abstract

    Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R. F.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results
    Meeting Abstract

    Morris, M. J.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Lacuna, K. P.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Hamilton, R. J.; Li, J. H.; Naini, V.; San Kheoh, T.; De Porre, P.; Molina, A.; Lelbowitz-Amit, R.; de Bono, J. S.; Scher, H. I.; Ryan, C. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Pathologic correlation of 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Martinez, D. F.; Autio, K. A.; Durack, J. C.; Humm, J.; Schoder, H.; Gavane, S. C.; Curtis, K. R.; Balakirsky, S. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Dittamore, R.; Louw, J.; Krupa, R.; Danila, D. C.; Arslan, Z.; Schreiber, N. A.; Bales, N.; Marrinucci, D.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save